The calpain-10 gene (CAPN10) has been implicated in type 2 diabetes (T2DM) susceptibility by both linkage and association in a Hispanic population from Starr County Texas. Common intronic variants seem to alter CAPN10 mRNA levels and were associated with insulin resistance but not diabetes in Pima Indians. The role of these variants in Caucasian populations is less clear. We found some evidence for linkage of T2DM to chromosome 2q approximately 20 cM proximal to the NIDDM1/CAPN10 locus. To test the hypothesis that CAPN10 is a diabetes susceptibility locus in Caucasian families at high risk for T2DM, we examined the influence of the three previously implicated CAPN10 variants on both diabetes risk and measures of insulin sensitivity and glucose homeostasis. 
T WIN AND FAMILY studies provide convincing evidence that type 2 diabetes (T2DM) is strongly inherited, with an increased risk to the sibling of a diabetic individual that is at least 3-fold higher than the population at large among individuals of European ancestry (1) . Nonetheless, genes for common T2DM have been elusive, probably because the disease is heterogeneous and multiple loci contribute to diabetes susceptibility in concert with environmental factors such as diet and activity. Recent studies have identified likely susceptibility loci on chromosomes 2q (NIDDM1) (2), 1q (3) (4) (5) , and 20 (6 -8) , among others. Of these loci, only NIDDM1 has been mapped to a single gene, calpain-10 (CAPN10). CAPN10 is a ubiquitously expressed member of the calpain-like cysteine protease family (9) . The risk of T2DM in Hispanic individuals at this locus can be accounted for by three variants, SNP-19, SNP-43, and SNP-63, which reside in introns of the CAPN10 gene. Heterozygosity for two haplotypes was associated with the highest risk for T2DM in Hispanic, German, and Finnish populations in the original observation, but this combination is unusual in Caucasian populations, and significance is thus uncertain. In vitro data suggested that SNP-43 altered CAPN10 expression, and the G/G genotype for SNP-43 also reduced CAPN10 messenger RNA in muscle biopsy specimens in Pima Indians (10) .
We have extensively characterized a cohort of multigenerational families of Northern European ancestry ascertained in Utah for at least two diabetic siblings. The most significant locus identified in these families maps to the ApoA2 region of chromosome 1q21-q23 (4). Although we found no evidence for linkage of T2DM to the NIDDM1 region of chromosome 2q, we did find suggestive linkage to a region approximately 15-20 cM proximal to CAPN10 (logarithm of odds ϭ 2.180 on affected sib pair analysis). Because replication of linkage even in the same population may occur this far from the initial observation (11) , this observation might also support a role for CAPN10 in susceptibility to T2DM in Caucasians.
To examine the role of CAPN10 in Utah families, we typed Abbreviations: AIR g , Acute insulin response to glucose; BMI, body mass index; CAPN10, calpain-10 gene; CI, confidence interval; DI, disposition index; FSIGT, frequently sampled iv glucose tolerance test; HOMA, homeostasis model assessment; OGTT, oral glucose tolerance test; OR, odds ratio; S I , insulin sensitivity index; , proportion of transmitted allelles; TDT, transmission disequilibrium test; T2DM, type 2 diabetes.
approximately 700 members of 63 families ascertained for Northern European ancestry and at least 2 siblings with T2DM. We have examined the association of each variant with T2DM, both individually and after assigning haplotypes, using the transmission disequilibrium test (TDT) (12) . We have also tested for an effect of each trait on glucose and insulin measures available from most nondiabetic family members, and on insulin sensitivity (S I ) measures available in a subset of family members.
Subjects and Methods Subjects
Families were ascertained for at least 2 siblings who were diagnosed with T2DM before age 65 yr. At most, one parent was known to have T2DM. All subjects were of Northern European ancestry. All available parents and siblings of the index sib pair were studied, as were any available offspring of diabetic siblings. Details of the study population have been described previously (4, 13) . The total study population comprised 854 available individuals from 63 kindreds. Genotypic data were available for 707 people for SNP-43, 700 individuals for UCSNP19, and 669 people for SNP-63. Each participant in the study gave informed consent under a protocol approved by the Institutional Review Board of the University of Utah Health Sciences Center, Salt Lake City. All clinical studies were performed at the University of Utah General Clinical Research Center.
Genotypic analysis
Initial typing of SNP43 was done by PCR-restriction fragment length polymorphism with enzyme Nsi I (9, 14) . After typing the entire pedigree membership twice and identifying obligate recombination events between closely spaced polymorphisms, we determined that our initial SNP typing was not accurate, and we retyped the full pedigree set using an oligonucleotide ligation assay. SNP-19 was typed with upstream primer GTTTGGTTCTCTTCAGCGTGGAG and downstream primer CATGAACCCTGGCAGGGTCTAAG. Products of 187 bp and 155 bp were separated on 2% agarose gels, visualized with ethidium bromide, and scored either by hand or semiautomatically using GeneProfiler software (Scanalytics, Inc.; Fairfax, VA) after capturing the gels as digital images using a UV transilluminator and Eagle Eye II (Stratagene, La Jolla, CA). Blinded duplicates were included in all assays.
Final typing for SNP-43 and SNP-63 was performed using an oligonucleotide ligation assay. All primers were designed from published CAPN10 sequence (9) . Amplification primers were CTCTGATTCCCAT-GGTCTGTAG and CACGCTTGCTGTGAAGTAATGC (SNP-43), and CTCAGCACCCAGTCCTACCA and GAGCAAATAAGGCGCAGGTЈ (SNP63). For SNP-43, allele specific primers were TCACGCTTGCTGC-GAAGTAAGGCG and TTTTTCACGCTTGCTGCGAAGTAAGGCA. The common SNP-43 oligonucleotide was TTTGAAGGTGAGGCTA-AGCCTTGACTTGGTGAGGATGGTCGTTTTACAACGTCGTG. For SNP-63, the allele specific oligonucleotides were CAGGGCCT-GACGGGGGTGGAGC and TTTTCAGGGCCTGACGGGGGTGGAGT, and the common oligonucleotide was GAGGGGGTGGGCCGCGTCT-GTGCAGGC. Allele-specific primers were labeled with ␥ 32 P-deoxy-ATP (6000 Ci/mmol; NEN Life Science Products, Boston, MA) using T 4 polynucleotide kinase (New England Biolabs, Inc., Beverly, MA). Samples were heated to 99 C for 30 min to inactivate Taq polymerase before ligation. Oligonucleotide ligations were carried out for 20 cycles of 94 C denaturation (20 sec) and 45 C ligation (1 min) using Taq DNA ligase (New England Biolabs, Inc.). Samples were separated on 8% polyacrylamide gels containing 8 m urea and imaged on a Storm 860 Phosphoimager (Molecular Dynamics, Inc., Sunnyvale, CA). Semiautomated scoring was performed using GeneProfiler on digitized images.
Statistical analysis
Likelihoods of the genetic models (15) were computed using the Pedigree Analysis Package (16) and the maxima were obtained using GEMINI (17) . Hypothesis testing was performed by comparing the likelihood of a submodel to the likelihood of a more general model.
Twice the natural logarithm of the ratio of the likelihoods has an asymptotic 2 distribution. The allele frequency of each SNP was estimated from unrelated pedigree members, assuming Hardy-Weinberg equilibrium but using genotypes on all pedigree members to provide information when individuals had not been genotyped. Haplotype frequencies were similarly estimated assuming tight linkage between the SNPs. We computed the probability of each genotype for an individual as the relative likelihood conditional on assignment of that genotype to the individual. The TDT (12) estimated the probability that a heterozygous parent transmitted each allele or haplotype to an affected offspring more often than expected by chance. Significance was tested through comparison of the likelihood with the estimated transmission probability to the likelihood with the transmission probability fixed at 50%. The odds ratio (OR) for each genotype was estimated relative to all other genotypes, similar to penetrance estimation within pedigrees. To correct the ORs for family membership, we estimated ORs of each genotype or haplotype combination against all other combinations after correcting for familial correlations and ascertainment.
For quantitative trait analyses, we tested only nondiabetic individuals. Insulin and glucose measures were log-transformed to normality and adjusted for age and gender. Mean trait values for heterozygous individuals were constrained to fall between mean values for homozygous individuals. For analysis among obese individuals, we defined obesity as body mass index (BMI) greater than 27.2 kg/m 2 for men and BMI greater than 26.9 kg/m 2 for women (18) . Analysis of individuals who had undergone frequently sampled iv glucose tolerance tests (FSIGT) was done using mixed-effects linear regression analysis in SPSS, Inc. v 10.1 (SPSS, Inc., Chicago, IL). Family membership was a random factor, genotype and diagnosis (normal and impaired glucose tolerance) were fixed factors, and age and ln-transformed BMI were covariates, as we have described previously (19, 20) . BMI, S I , acute insulin response to glucose (AIR g ), and disposition index (DI) were all ln-transformed before analysis. This analysis provides results comparable with that conducted in Pedigree Analysis Package to account for exact pedigree relationships (19) . All results are presented without correction for multiple testing, because we were testing prior hypotheses.
Results
The frequency of allele 1 for each SNP in our population was 0.74 Ϯ 0.02 for SNP-43, 0.43 Ϯ 0.02 for SNP-19, and 0.92 Ϯ 0.01 for SNP-63. These results were similar to those observed by Horikawa et al. (9) in European populations. The frequency of the predicted haplotypes is shown in Table 1 . Of the 804 predicted haplotypes, 89.4% were predicted with 90% or greater certainty, and 82.6% could be predicted with absolute certainty. We tested for a deviation from equal transmission of each allele from parent to affected offspring for each SNP. In contrast to our preliminary report based on restriction typing of SNP-43, we found no significant deviation from equal transmission of alleles to affected offspring for any SNP [proportion of alleles transmitted () ϭ 0.45, ϭ 0.47, and ϭ 0.53 for allele 1 for SNP-43, SNP-19, and SNP-63, respectively; P Ͼ 0.20 for all]. Transmission from males to affected offspring or females to affected offspring likewise (9), was not significantly different from 1.00 in our population and, if anything, tended to be protective (OR, 0.67). However, this haplotype combination is only predicted to represent 2.1% of Utah individuals; and consequently, our power to detect an effect of the magnitude previously described in Hispanic subjects was limited. Although the 111/221 haplotype seemed to significantly increase the risk of T2DM, this finding was true only after correcting for ascertainment and without correction for multiple analyses.
We next tested the effects of each CAPN10 SNP on quantitative traits measured during the oral glucose tolerance test (OGTT) and related to glucose homeostasis, including glucose and insulin. The significant results are shown in Table  3 . SNP-43 approached significance for fasting glucose ( 2 ϭ 5.27, P ϭ 0.07) when no specific genotype was tested. No other effect on glucose or insulin levels during the OGTT was found. When we tested the specific recessive hypothesis (SNP-43 1 1 or GG genotype against 1 2 or GA and 2 2 or AA), SNP-43 significantly, but marginally, increased the mean glucose from 4.7 mm to 4.9 mm (P ϭ 0.035). SNP-19 showed significant effects on fasting insulin ( 2 ϭ 6.62, P ϭ 0.04), 30-min glucose ( 2 ϭ 6.16, P ϭ 0.045), 60-min glucose ( 2 ϭ 8.74, P ϭ 0.013), and insulin resistance by homeostasis model assessment (HOMA) ( 2 ϭ 6.70, P ϭ 0.035) ( Table 3 ). The effect on fasting insulin was most marked among obese individuals ( 2 ϭ 10.20, P ϭ 0.0061; data not shown). Similarly, SNP-63 showed significant effects on total insulin area under the curve ( 2 ϭ 3.83, P ϭ 0.05), 90-min insulin ( 2 ϭ 5.41, P ϭ 0.020), and 2-h insulin ( 2 ϭ 5.37, P ϭ 0.021). Estimated genotypic means for significant associations with quantitative traits are shown in Table 3 .
Finally, we examined the effects of CAPN10 variants on S I determined by minimal model analysis of FSIGT data (21), insulin secretion determined as the AIR g , and the index of ␤-cell compensation (DI). Genotypic data were available for 117/128 possible individuals. SNP-19 was a significant determinant of S I (P ϭ 0.017), with most significance noted between individuals homozygous for the deletion allele, who had a higher S I , and all others (P ϭ 0.016). Marginal means are shown in Table 4 . In contrast, neither SNP-43 nor SNP-63 genotype significantly influenced S I , even when SNP-43 was considered to be recessive (P ϭ 0.4). None of the CAPN10 variants had a significant effect on insulin secretion (AIR g or DI).
Discussion
CAPN10 was first implicated in T2DM susceptibility by linkage in Hispanics from Starr County, Texas (2), and subsequently identified through linkage disequilibrium studies (9) . In Hispanics, Horikawa et al. (9) estimated the population-attributable risk at 14%, whereas the risk in Caucasians was estimated at only 4%. Although Horikawa et al. found the same risk haplotypes among Caucasians from Botnia; Finland; and Dresden, Germany, as in Hispanics (112/121), no haplotype combination was significant in the Caucasian populations individually. Likewise, SNP-43 was not significantly associated with T2DM in Pima Indians (10) . Similarly, none of the three SNPs tested here were associated with T2DM in a recent study of 743 sib pairs from the United Kingdom (22) . In contrast, a combined analysis of both Botnia and Dresden Caucasian populations suggested an OR of 3.16, with a 95% CI from 1. 19 -8.40 . Additional data supporting a role for CAPN10 variants includes evidence for in vitro effects of SNP-43 on gene expression (transcription) and on binding of nuclear extracts (9) . Among euglycemic Pima Indians, homozygosity for the G allele of SNP-43 resulted in higher fasting glucose, higher 2-h insulin, decreased glucose oxidation, and decreased glucose disposal (10) . Individuals with the SNP-43 G/G (1 1) genotype also showed 53% lower muscle CAPN10 mRNA levels.
In the present study, we successfully genotyped at least 669 individuals from 63 multigenerational families of Northern European descent, and we used a family-based approach to test the role of CAPN10 using the 3 variants to which most of the risk has been attributed (9). We did not find evidence for increased transmission of any allele for these 3 variants, and we found only marginal evidence for an increased risk of the 111/ 221 haplotype combination. Because we tested multiple haplotype combinations, and this was not the combination previ- ously shown to cause the highest risk, this finding must be interpreted with caution. Our results are consistent with the observations in the individual Botnia, Dresden, and United Kingdom populations and the results for SNP-43 in Pima Indians. Three possible explanations reconcile our findings with those of Horikawa et al. (9) . First, the high-risk haplotype combination, and particularly the 112 haplotype, is relatively rare among Caucasian populations; and thus, both the population attributable risk and our power to detect a significant effect are lower than in Hispanic individuals. Second, we have used TDT as applied to families with multiple affected individuals. Though the specific power of our method, compared with other TDT methods (20, (23) (24) (25) (26) , is unknown, in the absence of population stratification, TDT is probably less powerful than the case control design (27, 28) . We would be unable to detect excess transmission less than 57% for SNP-19 or SNP-43, and less than 64% for SNP-63. Thus, our failure to detect transmission disequilibrium for CAPN10 variants in the Utah population is consistent with a small effect of these CAPN10 variants on diabetes risk in this population and the low frequency of the highest risk haplotypes in Caucasians. Finally, the highest risk among Hispanic individuals was for the combination of haplotypes 112/121, rather than for individual haplotypes. TDT, which tests preferential transmission of a single haplotype, is not well suited to test models in which a specific haplotype combination confers the increased risk.
In contrast to our failure to confirm an association of CAPN10 variants with T2DM, we do confirm the findings of Baier et al. (10) and extend their results to an effect of the SNP-19 variant and to a Caucasian population. Although our data confirm that the SNP-43 GG (allele 1 in Tables 1-3 ) genotype very slightly raises fasting glucose in nondiabetic Caucasian individuals from families with a strong predisposition to T2DM, this finding is marginal and of uncertain significance. However, we find significant effects of SNP-19 on fasting insulin and HOMAderived insulin sensitivity (29) , effects of SNP-19 on postchallenge glucose levels, and significant effects of SNP-19 on S I from the FSIGT in a subset of individuals. Thus, like Baier et al. (10) , we show significant effects of CAPN10 on two measures of insulin sensitivity, albeit with SNP-19 rather than SNP-43. The effects of SNP-63, which is relatively rare in our population, on postchallenge insulin and insulin area under the curve, further support a CAPN10 role in insulin sensitivity. Finally, we suggest an interaction of CAPN10 variants and obesity in determining insulin sensitivity. That interaction might explain our failure to find an effect of SNP-43 on insulin sensitivity because BMI was a covariate in those analyses. Nonetheless, all of these effects are modest. Furthermore, because we tested a prior hypothesis, we did not correct for multiple testing. One might argue that correction for multiple testing would negate the modest P values found for our associations (P Ͼ 0.01 for most analyses). Additional studies in multiple populations are required, to address this concern.
A recent study suggested that calpains may regulate insulin secretion (30) . We found effects on neither AIR glucose nor DI in individuals who had undergone iv glucose tolerance testing, and no effect on the 30-min insulin during the OGTT. Thus, we were unable to demonstrate a role of these CAPN10 SNPs in insulin secretion. Recently, Stumvoll et al. (31) showed increased insulin secretion in German subjects who carried the SNP-43 GG genotype, using a hyperglycemic clamp study. That increase would seem to be the opposite of the expected effects to increase diabetes risk.
We have previously demonstrated suggestive linkage to chromosome 2q somewhat proximal to CAPN10 (4). Although CAPN10 variants clearly influence fasting glucose and insulin sensitivity among nondiabetic family members, our inability to demonstrate a convincing association of specific CAPN10 alleles with T2DM suggests that this finding of linkage probably cannot be attributed to CAPN10. No analysis in this region proximal to CAPN10 has reached genome-wide significance; and thus, evidence for linkage may be spurious. However, our results correspond to a similar peak in other studies (2) and may suggest a second susceptibility locus on chromosome 2. We are currently pursuing this possibility.
In conclusion, our results support CAPN10 as an influence on insulin sensitivity and fasting glucose as one of several loci influencing the risk of T2DM. However, this increased risk in our families, which were ascertained for a strong history of T2DM, seems to be modest. At least one other major susceptibility locus seems to segregate (4) in these families, and this locus (along with power considerations discussed above) likely Values are estimated from maximum likelihood analysis of full family data after log-transformation to normality and adjustment for age and gender (see Subjects and Methods).
IR, Insulin resistance. obscures the influence of CAPN10 on T2DM. Other very common variants also seem to modestly alter diabetes risk (32) (33) (34) , thus contributing the picture of a disease influenced by multiple common variants that differ in the degree of increased risk in different populations. The presence of multiple susceptibility and protective variants for complex diseases is perhaps not surprising, and this picture promises to become more complicated as susceptibility genes implicated in other genome scans are identified. Interestingly, we now report on a second population in which a biological effect of the CAPN10 variants can be demonstrated despite finding evidence for neither linkage nor association.
